I. M. Adcock (London, United Kingdom), P. O'Byrne (Hamilton, Canada)
IL-1β suppresses the maximal response to dexamethasone-induced GRE-luciferase activity in airway epithelial cells
R. Hayashi, P. J. Barnes, I. M. Adcock (London, United Kingdom)
|  |
Chemokine expression, apoptosis, and proliferation in the airway mucosa at steroid-mediated resolution of allergic rhinitis
L. Uller, C. Ahlstrom-Emanuelsson, M. Andersson, L. Greiff, C. G. A. Persson, J. S. Erjefalt (Stockholm, Sweden)
| |
The glucocorticoid nuclear action peculiarities in the steroid-resistant patients with severe bronchial asthma
N. J. Orlova, N. L. Shaporova, V. I. Trofimov, I. A. Fedoseeva (Saint-Petersburg, Russia)
| |
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide
A. Miller-Larsson, B. O. Axelsson, R. Brattsand, S. Edsbäcker, J. Ingelf (Lund, Sweden)
| |
Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations
R. Nave, K. Zech, H. Bliesath, T. D. Bethke (Konstanz, Germany)
| |
The potency ratio fluticasone propionate / budesonide
B. Stallberg, E. Pilman, B. E. Skoogh, B. A. Hermansson (Trosa, Helsingborg, Sweden)
| |
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma
H. Sacks, D. Gates, W. L. Kuo, L. Shneyer, K. Heithoff (Kenilworth, United States Of America)
| |
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
J. Karpel, W. Busse, H. Staudinger (Great Neck, Madison, Kenilworth)
| |
The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study
P. M. O‘Byrne, S. Pedersen, W. W. Busse, W. C. Tan, Y. Z. Chen, S. V. Ohlsson, A. Ullman, C. J. Lamm, R. A. Pauwels (Hamilton, Canada; Kolding, Denmark; Madison, ; Singapore, Singapore; Beijing, China; Lund, Sweden; Ghent, Belgium)
| |
Long-term safety data with once-daily budesonide in mild asthma: results from the START study
A. Sheffer, M. Silverman, A. Woolcock, P. Diaz Amor, B. Lindmark, F. Radner (Boston, United States Of America; Leicester, United Kingdom; Sydney, Australia; Santiago, Chile; Lund, Sweden)
| |
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study
K. B. Weiss, M. Buxton, L. F. Andersson, C. J. Lamm, B. Liljas, P. M. O‘Byrne, W. C. Tan, S. D. Sullivan (Chicago, Seattle, United States Of America; Uxbridge, United Kingdom; Basel, Sweden; Hamilton, Canada; Singapore, Singapore)
| |
Asthma control and medication use five years after early or delayed introduction of inhaled corticosteroids in asthma
O. Selroos, A. B. Löfroos, A. Pietinalho, H. Riska (Karis, Finland)
| |
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate
P. Houle, J. Eller, A. Wardlaw, P. Larivee, L. Ghaly, A. Harris (Quebec, Sherbrooke, Canada; Berlin, Germany; Glenfield, United Kingdom; Kenilworth, United States Of America)
| |
Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements
A. D. Smith, J. Cowan, D. R. Taylor (Dunedin, New Zealand)
| |
Asthma treatment based on sputum cell counts or usual clinical outcomes: the LOMA study
M. M. M. Pizzichini, L. Jayaram, P. Hussack, L. P. Boulet, C. Lemiere, A. Efthimiadis, A. Cartier, E. Pizzichini, F. E. Hargreave (Hamilton, Quebec, Montreal, Canada; Florianopolis, Brazil)
| |
Exsmoking discriminates between patients with difficult asthma
M. Chakra, A. Bourdin, H. Meziane, F. Paganin, I. Vachier, P. Godard, M. A. Vignola, P. Chanez (Montpellier, France)
| |
Predictors of asthma exacerbation after treatment cessation
M. Tonelli, D. Giannini, A. Di Franco, M. Zingoni, E. Bacci, F. L. Dente, B. Vagaggini, M. De Santis, A. Guerra, P. Paggiaro (Pisa, Italy)
| |
Effect of antiiflammatory treatment on bronchial wall thickness measured by HRCT in asthma
S. Baslilar, T. Y. Kuyucu, B. Saylan, N. Sariman, E. Derin (Istanbul, Turkey)
| |
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells
H. Boushey, P. Woodruff, G. Dolganov, P. Dorinsky, J. Fahy (San Francisco, Raleigh, United States Of America)
| |